UPDATED: Pfizer bets on Spero candidate, wading deeper alongside GSK and Roche into abandoned antibiotic market
Over the last year, Pfizer has been doing something strange for a large pharma company operating in the third decade of the 21st century: Investing in antibiotics.
First, they pledged $100 million for Big Pharma’s new antibiotic resistance fund. Then they scooped up a tiny virtual antibiotic startup from one of the founders of Tetraphase, a biotech that sold itself just a year ago. And then two months ago, they stepped up to buy out Amplyx and their anti-fungal drug, betting that they can make a dent in a separate but related infectious disease crisis.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,600+ biopharma pros reading Endpoints daily — and it's free.